# Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

> **NCT07371338** · PHASE1 · RECRUITING · sponsor: **Innopeutics Corporation** · enrollment: 6 (estimated)

## Conditions studied

- Parkinson Disease
- Parkinson's Disease

## Interventions

- **DRUG:** IPS101A

## Key facts

- **NCT ID:** NCT07371338
- **Lead sponsor:** Innopeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371338, "Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07371338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*